Eli Lilly: diabetes drug meets trial goal

(CercleFinance.com) - US biopharmaceutical company Eli Lilly and German partner Boehringer Ingelheim said on Thursday that their anti-diabetic treatment met its primary goal in a clinical trial.


The study met its primary endpoint, with Tradjenta demonstrating similar cardiovascular safety compared with placebo.

The trial included 6,979 adults with type-2 diabetes and high cardiovascular risk, the companies said.

Separately, Lilly said the U.S. label for once-weekly Trulicity has been updated to show the medicine's safety and efficacy in people with type-2 diabetes who have moderate to severe chronic kidney disease.

Copyright (c) 2018 CercleFinance.com. All rights reserved.